Nothing Special   »   [go: up one dir, main page]

HUE042877T2 - Gyógyászati kombinációk egy B-Raf inhibitor, egy EGFR inhibitor és adott esetben egy PI13K-alfa inhibitor tartalommal - Google Patents

Gyógyászati kombinációk egy B-Raf inhibitor, egy EGFR inhibitor és adott esetben egy PI13K-alfa inhibitor tartalommal

Info

Publication number
HUE042877T2
HUE042877T2 HUE13748243A HUE13748243A HUE042877T2 HU E042877 T2 HUE042877 T2 HU E042877T2 HU E13748243 A HUE13748243 A HU E13748243A HU E13748243 A HUE13748243 A HU E13748243A HU E042877 T2 HUE042877 T2 HU E042877T2
Authority
HU
Hungary
Prior art keywords
inhibitor
pi3k
optionally
alpha
pharmaceutical combinations
Prior art date
Application number
HUE13748243A
Other languages
English (en)
Inventor
Giordano Caponigro
Darrin Stuart
Parseval Laure Moutouh-De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE042877(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE042877T2 publication Critical patent/HUE042877T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE13748243A 2012-08-07 2013-08-05 Gyógyászati kombinációk egy B-Raf inhibitor, egy EGFR inhibitor és adott esetben egy PI13K-alfa inhibitor tartalommal HUE042877T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07

Publications (1)

Publication Number Publication Date
HUE042877T2 true HUE042877T2 (hu) 2019-07-29

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13748243A HUE042877T2 (hu) 2012-08-07 2013-08-05 Gyógyászati kombinációk egy B-Raf inhibitor, egy EGFR inhibitor és adott esetben egy PI13K-alfa inhibitor tartalommal

Country Status (39)

Country Link
US (1) US9474754B2 (hu)
EP (2) EP3574904A1 (hu)
JP (3) JP6342396B2 (hu)
KR (1) KR102112885B1 (hu)
CN (1) CN104519887B (hu)
AR (1) AR092045A1 (hu)
AU (1) AU2013299841B8 (hu)
CA (1) CA2879548C (hu)
CL (1) CL2015000294A1 (hu)
CO (1) CO7200273A2 (hu)
CY (1) CY1122143T1 (hu)
DK (1) DK2882440T3 (hu)
EA (1) EA028420B1 (hu)
EC (1) ECSP15008695A (hu)
ES (1) ES2717911T3 (hu)
GT (1) GT201500025A (hu)
HK (1) HK1211831A1 (hu)
HR (1) HRP20190537T1 (hu)
HU (1) HUE042877T2 (hu)
IL (1) IL236934B (hu)
IN (1) IN2015DN00450A (hu)
JO (1) JOP20130236B1 (hu)
LT (1) LT2882440T (hu)
MA (1) MA37829A1 (hu)
MX (1) MX359403B (hu)
MY (1) MY176031A (hu)
NZ (1) NZ703940A (hu)
PE (2) PE20150673A1 (hu)
PH (1) PH12015500246B1 (hu)
PL (1) PL2882440T3 (hu)
PT (1) PT2882440T (hu)
RS (1) RS58734B1 (hu)
SG (1) SG11201500321YA (hu)
SI (1) SI2882440T1 (hu)
TN (1) TN2015000027A1 (hu)
TR (1) TR201904980T4 (hu)
TW (1) TWI607754B (hu)
UA (1) UA115786C2 (hu)
WO (1) WO2014025688A1 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2882440T3 (pl) * 2012-08-07 2019-07-31 Novartis Ag Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa
EA201591842A1 (ru) 2013-03-21 2016-01-29 Новартис Аг Комбинированная терапия
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
DK3155126T3 (en) * 2014-06-16 2018-09-03 Worldwide Innovative Network METHOD OF CHOOSING PERSONAL TRIAL TREATMENT FOR CANCER TREATMENT
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
US10328065B2 (en) 2015-08-28 2019-06-25 Novartis Ag Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
US20180256557A1 (en) * 2015-08-28 2018-09-13 Giordano Caponigro Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
HUE060653T2 (hu) * 2016-06-03 2023-04-28 Array Biopharma Inc Gyógyászati kombinációk
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
RU2020108192A (ru) * 2017-08-03 2021-09-03 Новартис Аг Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf
SI3860998T1 (sl) 2018-10-05 2024-06-28 Annapurna Bio Inc. Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
BR112021022335A2 (pt) 2019-05-13 2021-12-28 Novartis Ag Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
US20250108051A1 (en) * 2022-01-27 2025-04-03 Tohoku University Therapeutic agent for cancer
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
AU2023351185A1 (en) * 2022-09-26 2025-04-24 Amgen Inc. Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU2008236562B2 (en) 2007-04-10 2013-11-07 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
RU2553379C2 (ru) * 2009-08-24 2015-06-10 Дженентек, Инк. ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK
AR077975A1 (es) * 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US20120202822A1 (en) * 2009-10-12 2012-08-09 Kurtis Earl Bachman Combination
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
RU2589695C2 (ru) * 2010-11-08 2016-07-10 Новартис Аг Использование производных 2-карбоксамид-циклоамино мочевины в лечении egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, нацеленным на члены egfr-семейства
CA2855245A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center Treatment of ovarian cancer with 2-amino-4h-naphtho[1,2-b]pyran-3-carbonitriles
BR112014011223A8 (pt) * 2011-11-11 2023-01-31 Novartis Ag Método de tratar uma doença proliferativa
PL2882440T3 (pl) * 2012-08-07 2019-07-31 Novartis Ag Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa

Also Published As

Publication number Publication date
CL2015000294A1 (es) 2015-05-08
PT2882440T (pt) 2019-04-23
CO7200273A2 (es) 2015-02-27
AU2013299841A8 (en) 2017-01-05
EP3574904A1 (en) 2019-12-04
CA2879548A1 (en) 2014-02-13
AU2013299841A1 (en) 2015-02-12
JOP20130236B1 (ar) 2021-08-17
MX359403B (es) 2018-09-26
PE20150673A1 (es) 2015-05-20
CA2879548C (en) 2020-07-21
JP2015524472A (ja) 2015-08-24
JP6342396B2 (ja) 2018-06-13
LT2882440T (lt) 2019-04-25
JP2020019780A (ja) 2020-02-06
MA37829A1 (fr) 2017-01-31
JP6595024B2 (ja) 2019-10-23
JP6974669B2 (ja) 2021-12-01
US9474754B2 (en) 2016-10-25
KR102112885B1 (ko) 2020-05-19
EA028420B1 (ru) 2017-11-30
EP2882440A1 (en) 2015-06-17
EA201590332A1 (ru) 2015-06-30
IN2015DN00450A (hu) 2015-06-26
EP2882440B1 (en) 2019-02-27
HK1204976A1 (en) 2015-12-11
CN104519887B (zh) 2017-06-27
BR112015002384A2 (pt) 2017-07-04
GT201500025A (es) 2017-09-28
NZ703940A (en) 2018-04-27
TN2015000027A1 (en) 2016-06-29
AU2013299841B2 (en) 2016-11-24
TWI607754B (zh) 2017-12-11
WO2014025688A1 (en) 2014-02-13
SI2882440T1 (sl) 2019-05-31
DK2882440T3 (da) 2019-05-06
BR112015002384A8 (pt) 2019-07-30
TW201410247A (zh) 2014-03-16
ES2717911T3 (es) 2019-06-26
AR092045A1 (es) 2015-03-18
KR20150040905A (ko) 2015-04-15
IL236934B (en) 2018-11-29
US20150265616A1 (en) 2015-09-24
MY176031A (en) 2020-07-22
HK1211831A1 (en) 2016-06-03
SG11201500321YA (en) 2015-04-29
ECSP15008695A (es) 2019-03-29
UA115786C2 (uk) 2017-12-26
JP2018109022A (ja) 2018-07-12
CN104519887A (zh) 2015-04-15
AU2013299841B8 (en) 2017-01-05
MX2015001732A (es) 2015-06-03
RS58734B1 (sr) 2019-06-28
PL2882440T3 (pl) 2019-07-31
PE20191655A1 (es) 2019-11-07
PH12015500246A1 (en) 2015-03-30
CY1122143T1 (el) 2020-11-25
TR201904980T4 (tr) 2019-05-21
HRP20190537T1 (hr) 2019-06-28
PH12015500246B1 (en) 2015-03-30

Similar Documents

Publication Publication Date Title
IL236934B (en) A pharmaceutical preparation containing a b-raf inhibitor, an egfr inhibitor and an optional pi3k-alpha inhibitor
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
GB201218801D0 (en) Device,method and software
GB2500915B (en) Arrangement and method
IL234850A0 (en) Rapid aneuploidy detection
EP2821748A4 (en) DEVICE FOR FINDING A BEACH AND METHOD FOR FINDING A BEACH
EP2637502A4 (en) MUTANT-SELECTIVE EGFR HEMMER AND USES THEREOF
EP2868008A4 (en) SIMULTANEOUS TRANSMISSION AND RECEPTION
HUE036907T2 (hu) Egyidejû adás és vétel
GB201906245D0 (en) A method and device
PL2831055T3 (pl) Zdolne do polimeryzacji alkilideno-1,3-dioksolan-2-ony i ich zastosowanie
EP2903772A4 (en) MATERIALS, METHODS AND DEVICES FOR CONNECTING LINES
SG11201404617SA (en) Mixing device, discharge device provided therewith, and discharge method
ZA201206179B (en) Software fingerprinting
SG11201501033UA (en) A device and a method for anastomosis
TWI562080B (en) Systes and methods for operation activation
EP2837627A4 (en) AMIDOPYRIDINE DERIVATIVE AND USE THEREOF
EP2842553A4 (en) ANALGESIC
EP2836857A4 (en) COUPLER, PROCESS AND APPLICATIONS
SG11201500474PA (en) Nutriculture member and nutriculture method
AU2013200291A1 (en) Methods and devices for context set selection
EP2821964A4 (en) COLOR SCALE DETERMINING DEVICE, COLOR SCANNING DETERMINING METHOD, AND COLOR SCANNING DETERMINING PROGRAM
EP2850785A4 (en) METHODS AND DEVICES FOR INITIATING A COMPLEMENTARY APPLICATION
EP2852079A4 (en) RECEIVING DEVICE AND RECEIVING METHOD
EP2869486A4 (en) RECEIVING DEVICE, METHOD, AND PROGRAM